Posts tagged T-cell
Provectus taking novel path to treat cancer

Rather than taking a biochemistry approach to develop drugs that kill cancer cells, Provectus Biopharmaceuticals (NYSE MKT:PVCT) is using physical chemistry by harnessing the unique properties of Rose Bengal, a first-in-class halogenated xanthene.

“We are taking a different type of molecule and a different basis for the mechanism of action than has been used in the industry,” Peter Culpepper, CFO and COO, says in an interview with

“Our PV-10 drug candidate has the potential to be employed in the treatment of all solid tumor cancers like melanoma, liver and breast, without the typical safety issues, as demonstrated thus far in clinical testing,” he contends. “Those are the cancers we’re focusing on.”

Read More
In conversation with Dr. Isaac Ciechanover

As president and CEO of Atara Biotherapeutics (NASDAQ:ATRA), Dr. Isaac Ciechanover has spent the past 20 years working with entrepreneurs and life sciences organizations to advance medicine through innovation and technology. He was a former partner in the life sciences practice at Kleiner Perkins Caufield & Byers and spent a decade as Celgene’s executive director of business development, spearheading venture capital, licensing and M&A activities with an aggregate transaction value of more than $6.7-billion. Dr. Ciechanover started Atara for personal reasons when his mother, Atara Ciechanover, for whom the company is named, was sick with ovarian cancer and there were no new therapies to treat the disease. Mrs. Ciechanover passed away in 2012. In this interview with, Dr. Ciechanover discusses the company’s clinical programs that target unique pathways and may pause or reverse patients’ underlying diseases.

Read More
In conversation with Allen Krantz

As the founder, president and CEO of Advanced Proteome Therapeutics (TSX-V:APC; Frankfurt:OE8), Dr. Allen Krantz has successfully transitioned a career in academia to the biotech sector. From 1968 to 1974, he was a member of the Faculty of Chemistry at the State University of New York at Stony Brook and from 1974 to 1981 he held appointments in both the Department of Chemistry and the Department of Pharmacological Sciences in the Medical School at the same institution. Then he began an extensive career in industry, with senior research postings at Syntex Research Canada and RedCell, the forerunner of ConjuChem, including a stint as the Directeur Scientifique of the European office in France in the 1990s. Dr. Krantz was responsible for transforming the company’s program to a practical focal point on human serum albumin as a carrier of drugs. In 2007, Advanced Proteome was created through a reverse takeover. In this interview with, Dr. Krantz discusses the company’s unique approach to developing a potential anti-cancer therapeutic.

Read More